Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years.  Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area.  There are now many approved therapies with proven track records.

As the technologies have lowered the barriers to entry for the industry, over 1,500 therapy or tools companies have been created or have become involved in this field.

This report, Kalorama’s Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023, tracks the dealmaking activities in cell and gene therapy since 2021.   The report provides informative graphs of quarterly trends from 2021-2023, and also includes the specific details of over 2,000 deals covering the period Q1 2022-Q3 2023.   A lot of attention and funding is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama’s tracked CGT investments, acquisitions, and other deals amounted to more than $25 billion in the first three quarters of 2023.  Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Kalorama’s report is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:

• Quarterly Funding Amounts 2021-2023
• Specific details of 2000+ CGT Deals from 2022-2023
• Venture Capital/Private Funding Round Amounts, By Quarter
• Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
• Deals by Type – Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
• Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
• Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)
• Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)

No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in more comprehensively.  As Cell and Gene Therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.